JP2019501132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501132A5 JP2019501132A5 JP2018526675A JP2018526675A JP2019501132A5 JP 2019501132 A5 JP2019501132 A5 JP 2019501132A5 JP 2018526675 A JP2018526675 A JP 2018526675A JP 2018526675 A JP2018526675 A JP 2018526675A JP 2019501132 A5 JP2019501132 A5 JP 2019501132A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- fab fragment
- antibody fab
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259227P | 2015-11-24 | 2015-11-24 | |
| US62/259,227 | 2015-11-24 | ||
| PCT/US2016/063587 WO2017091719A1 (en) | 2015-11-24 | 2016-11-23 | Anti-complement factor c1q fab fragments and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501132A JP2019501132A (ja) | 2019-01-17 |
| JP2019501132A5 true JP2019501132A5 (enExample) | 2020-01-09 |
| JP6976943B2 JP6976943B2 (ja) | 2021-12-08 |
Family
ID=58763681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526675A Active JP6976943B2 (ja) | 2015-11-24 | 2016-11-23 | 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10723788B2 (enExample) |
| EP (1) | EP3380518A4 (enExample) |
| JP (1) | JP6976943B2 (enExample) |
| KR (1) | KR102877741B1 (enExample) |
| CN (2) | CN115260310B (enExample) |
| AU (1) | AU2016361517C1 (enExample) |
| BR (1) | BR112018010360A2 (enExample) |
| CA (1) | CA3006092A1 (enExample) |
| IL (2) | IL296130A (enExample) |
| SG (1) | SG11201803703UA (enExample) |
| WO (1) | WO2017091719A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| KR102321320B1 (ko) | 2013-07-09 | 2021-11-03 | 애넥슨, 인코포레이티드 | 항-보체 인자 ｃ１ｑ 항체 및 이의 용도 |
| US10316081B2 (en) | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
| BR112018010360A2 (en) | 2015-11-24 | 2018-12-04 | Annexon, Inc. | anti-c1q complement factor fab fragments and uses thereof |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| MX2020010528A (es) * | 2018-04-13 | 2020-11-06 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-componente de complemento y metodos de uso. |
| FI3893924T3 (fi) | 2018-12-13 | 2024-10-04 | argenx BV | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021076991A1 (en) * | 2019-10-17 | 2021-04-22 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| CN110716038B (zh) * | 2019-10-23 | 2022-08-30 | 俞梦越 | 一种急性冠脉综合征补体检测试剂盒及其使用方法 |
| CA3177879A1 (en) * | 2020-05-05 | 2021-12-02 | Jeanne T. PAZ | Compositions and methods for treating epilepsy |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| CN112837822B (zh) * | 2020-09-24 | 2023-05-02 | 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) | 预测covid-19患者发生轻至重度进展的标志物及试剂盒和建立方法 |
| AU2021361067A1 (en) * | 2020-10-16 | 2023-06-01 | Annexon, Inc. | Compositions and methods for treating blood disorders |
| CA3200976A1 (en) * | 2020-12-04 | 2022-06-09 | Anita GROVER | Compositions and methods for treating ocular diseases |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| WO2023130001A1 (en) * | 2021-12-30 | 2023-07-06 | Annexon, Inc. | Compositions and methods for treating huntington's disease |
| EP4518896A1 (en) * | 2022-04-29 | 2025-03-12 | Annexon, Inc. | Compositions and methods for treating ocular diseases |
| CA3253133A1 (en) * | 2022-05-13 | 2023-11-16 | Annexon Inc | COMPOSITIONS AND METHODS OF TREATMENT OF LUPUS NEPHRITIS |
| CN119371528B (zh) * | 2024-10-30 | 2025-06-24 | 泰州市人民医院 | 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US20020058311A1 (en) | 1995-06-13 | 2002-05-16 | Browne Michael Jospeh | Chimeric leptin fused to immunoglobulin domain and use |
| KR100532178B1 (ko) | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-ＣＤ11ａ 항체 |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| KR20010023325A (ko) | 1997-08-26 | 2001-03-26 | 리스 데브라 케이. | 함지방세포-특이적 단백질 상동체 |
| US20030170781A1 (en) | 1999-07-01 | 2003-09-11 | Zymogenetics, Inc. | Secreted protein zacrp4 |
| WO2002005634A2 (en) | 2000-07-13 | 2002-01-24 | University Of South Florida | Transgenic animal and methods |
| US6872559B2 (en) | 2000-10-26 | 2005-03-29 | Wisconsin Alumni Research Foundation | E. coli O157:H7 C1 esterase inhibitor-binding protein and methods of use |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| CA2478313A1 (en) | 2001-11-07 | 2003-06-26 | Human Genome Sciences, Inc. | 41 human secreted proteins |
| US20040248156A1 (en) | 2001-12-03 | 2004-12-09 | Tianhua Hu | Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides |
| US20050214786A1 (en) | 2002-02-22 | 2005-09-29 | Human Genome Sciences, Inc. | 26 human secreted proteins |
| JP4768620B2 (ja) | 2003-05-15 | 2011-09-07 | ジェネンテック， インコーポレイテッド | 敗血症の予防及び治療のための方法及び組成物 |
| WO2005002513A2 (en) | 2003-06-16 | 2005-01-13 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| WO2005002512A2 (en) | 2003-06-19 | 2005-01-13 | University Of Rochester | Immunotherapeutic vaccine strategy |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2005063816A2 (en) | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| US7544855B2 (en) | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US8420783B2 (en) | 2004-12-08 | 2013-04-16 | Immunomedics, Inc. | Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases |
| AU2005227420B2 (en) | 2005-10-14 | 2013-05-09 | Alltech, Inc. | Method and compositions for altering cell function |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| BRPI0709050B1 (pt) | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| EP2380907B1 (en) | 2006-09-05 | 2016-11-30 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN101657097A (zh) | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| MX2010006422A (es) | 2007-12-11 | 2010-06-25 | Glaxo Group Ltd | Proteinas de union a antigenos. |
| CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| CN105866426B (zh) | 2008-12-01 | 2018-11-23 | 小利兰·斯坦福大学托管委员会 | 用于检测补体结合性抗体的方法和组合物 |
| EP2426916A4 (en) | 2009-04-28 | 2017-09-06 | Panasonic Corporation | Receiver |
| WO2012067267A1 (en) | 2010-11-18 | 2012-05-24 | Takahiro Ochi | TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| US9127061B2 (en) | 2011-06-24 | 2015-09-08 | Perseus Proteomics Inc. | Anti-human P-cadherin (CDH3) recombinant antibody |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| JP6849868B2 (ja) | 2012-05-10 | 2021-03-31 | ザイムワークス，インコーポレイテッド | シングルアーム一価抗体構築物およびその用途 |
| CN118924900A (zh) | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| KR102321320B1 (ko) | 2013-07-09 | 2021-11-03 | 애넥슨, 인코포레이티드 | 항-보체 인자 ｃ１ｑ 항체 및 이의 용도 |
| US10316081B2 (en) * | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
| BR112018010360A2 (en) | 2015-11-24 | 2018-12-04 | Annexon, Inc. | anti-c1q complement factor fab fragments and uses thereof |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| WO2018017711A1 (en) * | 2016-07-19 | 2018-01-25 | Annexon, Inc. | Compositions and methods for treating frontotemporal dementia |
| EP4196163A4 (en) | 2020-08-14 | 2024-08-28 | Chugai Seiyaku Kabushiki Kaisha | ONE-ARM ANTIGEN-BINDING MOLECULES AND THEIR USES |
| CA3200976A1 (en) | 2020-12-04 | 2022-06-09 | Anita GROVER | Compositions and methods for treating ocular diseases |
-
2016
- 2016-11-23 BR BR112018010360-8A patent/BR112018010360A2/en active Search and Examination
- 2016-11-23 KR KR1020187017912A patent/KR102877741B1/ko active Active
- 2016-11-23 US US15/360,549 patent/US10723788B2/en active Active
- 2016-11-23 CA CA3006092A patent/CA3006092A1/en active Pending
- 2016-11-23 CN CN202210711282.0A patent/CN115260310B/zh active Active
- 2016-11-23 WO PCT/US2016/063587 patent/WO2017091719A1/en not_active Ceased
- 2016-11-23 EP EP16869264.8A patent/EP3380518A4/en active Pending
- 2016-11-23 JP JP2018526675A patent/JP6976943B2/ja active Active
- 2016-11-23 SG SG11201803703UA patent/SG11201803703UA/en unknown
- 2016-11-23 IL IL296130A patent/IL296130A/en unknown
- 2016-11-23 AU AU2016361517A patent/AU2016361517C1/en active Active
- 2016-11-23 CN CN201680079670.4A patent/CN108779171B/zh active Active
-
2018
- 2018-05-01 IL IL259079A patent/IL259079B2/en unknown
-
2020
- 2020-06-25 US US16/911,954 patent/US11999779B2/en active Active
-
2024
- 2024-05-31 US US18/680,437 patent/US20250002567A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501132A5 (enExample) | ||
| JP2018501813A5 (enExample) | ||
| JP2016526393A5 (enExample) | ||
| JP7627045B2 (ja) | 新規抗－ｃ－ｋｉｔ抗体 | |
| US20250002567A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| US9856321B2 (en) | Anti-DR5 antibodies, polynucleotides and methods | |
| JP2019518459A (ja) | Ｌａｇ−３抗体、その抗原結合フラグメント、およびそれらの医薬的用途 | |
| FI3019240T3 (fi) | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä | |
| WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| JP2011504872A5 (enExample) | ||
| JPWO2020014617A5 (enExample) | ||
| EP3990488A1 (en) | Semaphorin 3a antibodies and uses thereof | |
| US12486322B2 (en) | Anti-complement factor C1q antibodies with single binding arms and uses thereof | |
| US20240376186A1 (en) | C3b-Binding Fusion Proteins | |
| NZ732156B2 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| NZ742877B2 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| NZ732156A (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| HK40083120A (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| NZ769628B2 (en) | Humanized anti-complement factor C1q antibodies and uses thereof | |
| CN119907685A (zh) | 用于抗c1q抗体的制剂 | |
| CN113621066A (zh) | 一种抗pd-1抗体及其晶体制备方法 | |
| HK1262078A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| HK1262078B (en) | Anti-complement factor c1q fab fragments and uses thereof |